OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
Our Founder's Story
Hear our CEO and Founder Mireille Kamariza, Ph.D. talk about her story, and how DMN-Tre could increase the speed, accuracy, and availability of tuberculosis treatment.
Publications
- Rapid detection of Mycobacterium tuberculosis in sputum with a solvatochromic trehalose probe. Science Translational Medicine Vol. 10, Issue 430 (2018)
- Sensitivity Optimisation of Tuberculosis Bioaerosol Sampling. PLoS ONE 15(9): e0238193 (2020)
- Pore-forming Esx proteins mediate toxin secretion by Mycobacterium tuberculosis. Nature Communications Vol. 12, Article number: 394 (2021)
- Capture and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis bioaerosols. bioRxiv preprint (2019)
- Towards Mycobacterium tuberculosis detection at the point-of-care: a brighter solvatochromic probe permits the detection of mycobacteria within minutes. bioRxiv preprint (2020)
Kamariza et al 2018_Science Transl Med (pdf)
DownloadNews
OliLux Biosciences kickstarts a new partnership with the R2D2 TB Network
OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
This new collaboration with the R2D2 TB Network seeks to facilitate further development of DMN-Tre as a next-generation drug susceptibility test reagent by clinically evaluating it in diverse and relevant study sites across the globe.
OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
Spring 2021
OliLux Biosciences will expand its research and clinical operations to develop diagnostic and treatment monitoring tools for the rapid detection and management of tuberculosis in resource-limited settings.
We're honored to speak at the inaugural Stanford . Berkeley . UCSF Next Gen Faculty Symposium
OliLux Biosciences raises $400,000 from Open Philanthropy to tackle drug-resistant tuberculosis
We're honored to speak at the inaugural Stanford . Berkeley . UCSF Next Gen Faculty Symposium
Fall 2020
The Stanford.Berkeley.UCSF Next Generation Faculty Symposium is a platform designed to highlight the work of exceptional early-career scientists in the broad field of quantitative biological and biomedical sciences, with a track record of research productivity and demonstrated contributions to enhancing diversity, equity, and inclusion in STEM.
Our work highlighted by C&EN Magazine as chemistry that will have a global impact
Our work highlighted by C&EN Magazine as chemistry that will have a global impact
We're honored to speak at the inaugural Stanford . Berkeley . UCSF Next Gen Faculty Symposium
Summer 2020
Co-founder & CEO Mireille Kamariza was one of C&EN's Talented 12 young rising stars who are using chemical know-how to change the world.
MediLux Biosciences Pte. Ltd. established as a subsidiary in Singapore
Our work highlighted by C&EN Magazine as chemistry that will have a global impact
MediLux Biosciences Pte. Ltd. established as a subsidiary in Singapore
Fall 2019
By setting up MediLux Biosciences Pte. Ltd. in Singapore, OliLux affirms our global commitment to fight TB by expanding our footprint to Southeast Asia.
OliLux was selected for StartX Spring 2019!
Our work highlighted by C&EN Magazine as chemistry that will have a global impact
MediLux Biosciences Pte. Ltd. established as a subsidiary in Singapore
Spring 2019
StartX is an educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence.
OliLux was selected for Cardinal Ventures program Fall 2018!
Blog post about our work in South Africa. Published by Huffington Post South Africa.
Blog post about our work in South Africa. Published by Huffington Post South Africa.
Fall 2018
Cardinal Ventures is a startup accelerator on the Stanford campus run by students, for students.
Blog post about our work in South Africa. Published by Huffington Post South Africa.
Blog post about our work in South Africa. Published by Huffington Post South Africa.
Blog post about our work in South Africa. Published by Huffington Post South Africa.
Winter 2018
"We’ve come up with a TB test that’s cheaper, quicker and more accurate" written by our very own Bavesh Kana, PhD.
We're in the news! Published by HHMI News.
Blog post about our work in South Africa. Published by Huffington Post South Africa.
The research article on DMN-Tre, our first product, is published in Science Translational Medicine
The research article on DMN-Tre, our first product, is published in Science Translational Medicine
The research article on DMN-Tre, our first product, is published in Science Translational Medicine
The research article on DMN-Tre, our first product, is published in Science Translational Medicine
Winter 2018
Kamariza, M., et al., "Rapid detection of Mycobacterium tuberculosis in sputum with a solvatochromic trehalose probe." Science Translational Medicine. Vol. 10, Issue 430, eaam6310.
The first news piece about our reagent! Published by Science Magazine.
The research article on DMN-Tre, our first product, is published in Science Translational Medicine
The first news piece about our reagent! Published by Science Magazine.
Summer 2016
"Simple test could quickly detect tuberculosis in developing countries" written by Robert F. Service.
Featured in
Copyright © 2021 OliLux Biosciences Inc., a Public Benefit Corporation.
All Rights Reserved.
Powered by GoDaddy